Authors
Loading...
Retrospective analysis shows durable complete response improves survival in high-risk myelodysplastic syndromes, suggesting better drug development metrics.
Ali et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: